尼妥珠单抗联合PF方案诱导治疗局部晚期鼻咽癌的多中心临床研究

[1] Lang J, Gao L, Guo Y, et al. Comprehensive treatment of
squamous cell cancer of head and neck: hinese expert consensus
2013[J]. Future Oncol, 2014, 10(9): 1635-48.
[2] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy
plus concurrent chemoradiotherapy versus concurrent
chemoradiotherapy alone in locoregionally advanced
nasopharyngeal carcinoma: a phase 3, multicentre,randomised
controlled trial[J]. Lancet Oncol, 2016, 17(11): 1509-20.
[3] Kong L, Zhang Y, Hu C, et al. Effects of Induction Docetaxel,
Platinum, and Fluorouracil Chemotherapy in Patients With Stage
Ⅲ or ⅣA/B Nasopharyngeal Cancer Treated With Concurrent
Chemoradiation Therapy: Final Results of 2 Parallel Phase 2
Clinical Trials[J]. Cancer, 2017, 123(12): 2258-67.
[4] 马雄辉, 梁彩霞, 江丹贤, 等. TPF诱导化疗或PF诱导化疗
联合同期放化疗治疗局部晚期鼻咽癌的临床观察[J]. 中国
癌症杂志, 2016, 26(12): 1018-24. [Ma XH, Liang CX, Jiang
DX, et al. Clinical observation of TPF induction chemotherapy
versus PF induction chemotherapy combined with concurrent
chemoradiotherapy for the treatment of locoregionally advanced
nasopharyngeal carcinoma[J]. Zhongguo Ai Zheng Za Zhi, 2016,
26(12): 1018-24.]
[5] 杨佑琦, 区晓敏, 周鑫, 等. GP、PF及TPF方案化疗联合调强适
形放疗治疗鼻咽癌的临床疗效[J]. 中国癌症杂志, 2018, 28(8):
602-8. [Yang YQ, Ou XM, Zhou X, et al. Clinical efficacy of GP,
PF and TPF chemotherapy combined with intensity-modulated
radiotherapy for nasopharyngeal carcinoma[J]. Zhongguo Ai
Zheng Za Zhi, 2018, 28(8): 602-8.]
[6] Herbst RS, Shin DM. Monoclonal antibodies to target epidermal
growth factor receptor-positive tumors: a new paradigm
for cancer therapy[J]. Cancer, 2002, 94(5): 1593-611.
[7] Sun W, Long G, Wang J, et al. Prognostic role of epidermal
growth factor receptor in nasopharyngeal carcinoma: a metaanalysis[
J]. Head Neck, 2014, 36(10): 1508-16.
[8] Ma X, Huang J, Wu X, et al. Epidermal growth factor
receptor could play a prognostic role to predict the outcome
ofnasopharyngeal carcinoma: A meta-analysis[J]. Cancer
Biomark, 2014, 14(4): 267-77.
[9] Peng H, Tang LL, Liu X, et al. Anti-epidermal growth factor
receptor therapy concurrently withinduction chemotherapy in
locoregionally advancednasopharyngeal carcinoma[J]. Cancer Sci,
2018, 109(5): 1609-16.
[10] 黄晓东, 易俊林, 高黎, 等. 抗表皮生长因子受体单克隆抗体
h-R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J]. 中华肿瘤杂
志, 2007, 29(3): 197-201. [Huang XD, Yi JL, Gao L, et al. Multicenter
phase Ⅱ clinical trial of humanized anti-epidermal factor
receptor monoclonal antibody h-R3 combined with radiotherapy
for locoregionally advanced nasopharyngeal carcinoma[J].
Zhonghua Zhong Liu Za Zhi, 2007, 29(3): 197-201.]
[11] Kong L, Lin Q, Lu JJ, et al. Radiation plus concurrent
nimotuzumab versrs CDDP in locally advanced nasopharyngeal
cancer: resuls of 3 randomised trial[C]. 2016, ASCO Abstract No:
6002.
[12] Wang F, Jiang C, Ye Z, et al. Efficacy and safety of nimotuzumab
with neoadjuvantchemotherapy followed by concurrent
chemoradiotherapy forlocoregionally advanced nasopharyngeal
carcinoma[J]. Oncotarget, 2017, 8(43): 75544-56.